Ligand Directed NIR-based Theranostic Prodrugs for Prostate Cancer

Project description

Ligand-directed NIR-based theranostic prodrugs for prostate cancer

Prostate cancer is currently the most common cancer in men and remains the leading cause of death. Current strategies still carry severe side effects and offer limited benefits to the patient, associated with non-specific delivery of an anticancer drug to the target tissue. The EU-funded ClickandTreatCancer project is working on developing a strategy to deliver anticancer drugs selectively to prostate cancer cells while monitoring in real-time drug release and efficacy in vivo. The project entails the creation of a protocol based on a DT-diaphorase-activated, DUPA-guided model combined with cancer cell elimination by near-infrared (NIR) light-regulated theranostic strategy. The technology shows great promise in that it can easily be adapted for the treatment of other cancer types.

Fields of science

• medical and health sciences › clinical medicine › oncology › prostate cancer
• social sciences › sociology › demography › mortality

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Net EU contribution

€ 159 815,04

Address

Avenida Prof Egas Moniz
1649 028 Lisboa
Portugal

Region

Continente › Área Metropolitana de Lisboa › Área Metropolitana de Lisboa

Activity type

Research Organisations

Links

Other funding

€ 0,00